Clinical trial · Interventional
Irreversible Electroporation(IRE) For Unresectable Renal Tumors
Irreversible Electroporation (IRE) for Unresectable Renal Tumors: Phase I and Phase II Clinical Trial
NCT02335827CI-TRIAL-00053673IREcompletedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to investigate the safety and efficacy of irreversible electroporation (IRE) for unresectable renal tumors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Renal Tumor | Kidney Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| irreversible electroporation | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Group A
- description
- irreversible electroporation with voltage in level A for renal tumors
- interventionNames
- Procedure: irreversible electroporation
- type
- EXPERIMENTAL
- label
- Group B
- description
- irreversible electroporation with voltage in level B for renal tumors
- interventionNames
- Procedure: irreversible electroporation
- type
- EXPERIMENTAL
- label
- Group C
- description
- irreversible electroporation with voltage in level C for renal tumors
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * unresectable kidney tumors * patients refused surgical therapy * Karnofsky-index \>70% * Age ≥ 18 and ≤ 80 years * life expectancy ≥ 12 month * compliance of the patient taking part in a study * informed consent Exclusion Criteria: * violation against one or more inclusion criteria * an estimated glomerular filtration rate (eGFR) of \< 30 mL/min/1.73 m2 * QT-interval \>550 ms or cardiac arrhythmias or condition after myocardial infarction, that make an ECG-synchronisation unfeasible * active infection or severe health interference, that make taking part in a study unfeasible * pregnancy, lactation period * general contraindications for anesthesia, endotracheal anesthesia and muscle relaxation * psychiatric disorders that make taking part in a study or giving informed consent unfeasible * haemorrhage, impossible intermission of taking blood thinner, untreatable thrombophilia * thromboplastin time ≤50 %, thrombocytes ≤50 Gpt/L; partial thromboplastin time \>50 * untreated urinary retention * severe hepatic dysfunction * any other clinically important renal, hematological, metabolic, neurological, gastrointestinal, hepatic or pulmonary disorders or dysfunctions preventing study participation (investigator's assessment) * taking part in another clinical study for renal tumor.
References
Publications (0)
Data not yet available
No reference posted for this study.